当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2020-03-09 , DOI: 10.1021/acs.jmedchem.9b01976
Scott J Hecker 1 , K Raja Reddy 1 , Olga Lomovskaya 1 , David C Griffith 1 , Debora Rubio-Aparicio 1 , Kirk Nelson 1 , Ruslan Tsivkovski 1 , Dongxu Sun 1 , Mojgan Sabet 1 , Ziad Tarazi 1 , Jonathan Parkinson 1 , Maxim Totrov 2 , Serge H Boyer 1 , Tomasz W Glinka 1 , Orville A Pemberton 3 , Yu Chen 3 , Michael N Dudley 1
Affiliation  

Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory to inhibition by agents recently introduced. Most important among these are the class B (metallo) enzyme NDM-1 of Enterobacteriaceae and the class D (OXA) enzymes of Acinetobacter baumannii. Continuing the boronic acid program that led to vaborbactam, efforts were directed toward expanding the spectrum to allow treatment of a wider range of organisms. Through key structural modifications of a bicyclic lead, stepwise gains in spectrum of inhibition were achieved, ultimately resulting in QPX7728 (35). This compound displays a remarkably broad spectrum of inhibition, including class B and class D enzymes, and is little affected by porin modifications and efflux. Compound 35 is a promising agent for use in combination with a β-lactam antibiotic for the treatment of a wide range of multidrug resistant Gram-negative bacterial infections, by both intravenous and oral administration.

中文翻译:

发现环硼酸QPX7728,一种丝氨酸和金属β-内酰胺酶的超广谱抑制剂。

尽管β-内酰胺酶抑制剂领域取得了重大进展,但某些酶仍对最近引入的药物的抑制作用具有抵抗力。其中最重要的是肠杆菌科的B类(金属)酶NDM-1和鲍曼不动杆菌的D类(OXA)酶。继续实施导致vaborbactam的硼酸计划,努力扩大光谱范围,以治疗更广泛的生物。通过双环先导的关键结构修饰,抑制谱逐步提高,最终得到QPX7728(35)。该化合物显示出极大的抑制谱,包括B类和D类酶,几乎不受孔蛋白修饰和外排的影响。化合物35 是与β-内酰胺类抗生素组合使用的有前途的药物,可通过静脉内和口服给药治疗多种多重耐药性革兰氏阴性细菌感染。
更新日期:2020-03-09
down
wechat
bug